sukus, NWBO can only share information publicly that completely follows applicable protocol of data generation as specified by regulatory guidances as they apply to clincial studies, at least during this stage of development/approval. They can share supportive studies with the RA's but are very limited in their public sharing at this time. This is especially true where new approaches like ECA's are concerned. RA's want such new approaches utilized conservatively and the time to add supportive information is just not now and certainly not with the public.
GLTA, much more to come here
Market Data 
Markets 
AI
